Microbiome Drugs Market – Global Industry Analysis and Forecast (2022-2029)

Microbiome Drugs Market is expected to reach US$ 813.93 Mn by 2029 from US$ 266.07 Mn in 2021, at a CAGR of 15 % during the forecast period.

Microbiome Drugs Market Overview:

The Microbiome is being recognised as a central mediator of drug action, as it regulates many aspects of host health and disease. The Microbiomes from the human body are used for disease care. These medications extracted from microbiomes help the physician in making a more accurate diagnosis of the disease.Microbiome Drugs MarketTo know about the Research Methodology :- Request Free Sample Report

Global Microbiome Drugs Market Dynamics:

The increasing prevalence of lifestyle disorders drives the global market. The human microbiome has been linked to lifestyle disorders such as cancer, diabetes, and obesity. Changing lifestyle and social norms have a direct effect on the microbiome. Making the alterations to the human microbiome will aid in the prevention of lifestyle diseases. According to the World Health Organisation, 13% of the world's adult population was obese in 2017. In terms of minimising the adverse effects induced by the overuse of antibiotics, technological advances done in human microbiome drugs and diagnostics have outperformed traditional approaches. The growth of this market is being driven by rising cases of chronic diseases such as diabetes, and the ability of drugs to diagnose them at the early stage. Also, increased awareness among people to maintain a healthy lifestyle further boosts the market growth. Other factors such as the growing geriatric population, rise in healthcare expenditure and the demand for successful procedures and safe medications are expected to fuel market growth. Microbiome therapy has grown in popularity over the last decade. The National Institutes of Health (NIH) spent USD 215 million on the Human Microbiome Project (HMP) and USD 728 million on extramural human microbiome research activities outside of the HMP during the last decade. Rising pharmaceutical company partnership for the production of novel drugs is another important factor impacting the market growth. The Seres Therapeutics in the United States and Nestlé Health Science collaborated to develop and commercialise a broad product pipeline for ulcerative colitis and C. difficile infection. However, in developing regions, lack of knowledge about the health benefits of probiotics and prebiotics, stringent government regulations, is expected to limit the market growth. Along with this, lack of regulatory pathways and delays in the launch of microbiome products are also expected to hamper the market's growth during the forecast period. The report has profiled seventeen key players in the market from different regions. However, the report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for a future hot spot in APAC region.

Global Microbiome Drugs Market Segment Analysis:

The Global Microbiome Drugs Market is segmented on the basis of Product Type, Application and End-Users. Based on Product Type, the Probiotics segment accounted for the largest market share in 2021. Due to an increase in the prevalence of health issues, increased understanding of the relationship between nutrition, diet, and health, and increased use of probiotics in the dairy and other foods industry, this segment is expected to dominate the market during the forecast period. Next-generation probiotics, such as Akkermansia muciniphila, Bacteroides uniformis, Clostridium clusters IV, XIVa, and XVIII, and F. prausnitzii, have been established as a result of microbiome research. With improved clinical results, these new-age probiotics are expected to boost the demand in the coming years. Furthermore, the prebiotics segment is expected to rise at the fastest pace during forecast years. Based on Application, the therapeutics segment is expected to dominate the global market during the forecast period. The major factor driving the growth of this segment is an increase in funding for R&D in microbiome-based therapies around the world. Along with this, technological advances, an increase in the number of clinical trials, and increasing partnerships between key market players and research institutes all contribute to market development. Microbiome therapeutics gained popularity by its newfound application in the treatment of COVID-19. For example, the University of Zurich was studying the microbiota in COVID-19 patients in 2021 in order to develop potential preventive and therapeutic approaches (MICRO-COV). Positive findings from these research studies would open up new growth opportunities for the segment under consideration.

Microbiome Drugs MarketGlobal Microbiome Drugs Market Regional Insights:

North America is expected to dominate the global market during the forecast period. North America accounted for more than 45% of the global economy in 2021. The presence of industry-academic partnership, government-funded microbiome ventures, and committed microbiome-based small start-ups are all contributing to the market's development. Because of the increasing incidences of lifestyle-related diseases and autoimmune disorders in the region, North America dominates the human microbiome sector. The highly profitable growth can also be attributed to the existence of a large drug pipeline. Seres Therapeutics' stool-derived therapy for recurrent Clostridium difficile infection cleared phase-III clinical trials in 2021. The report also helps in understanding the Global Microbiome Drugs Market dynamics, structure by analyzing the market segments and project the Global Microbiome Drugs Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Microbiome Drugs Market make the report investor’s guide.

Global Microbiome Drugs Market Key Developments:

• Kaleido Biosciences began a randomised clinical trial of KB109, a microbiome metabolic therapy, in outpatients with mild-to-moderate COVID-19 in March 2021. As a result, it is projected to improve the demand studied in the future. • Siolta Therapeutics was recently added to the Microbiome Therapeutics Innovation Group's (MTIG) consortium of companies leading the R&D of microbiome therapeutics and microbiome-based items. • AstraZeneca and Seres Therapeutics collaborated with each other in March 2021 to examine how the microbiome system affects a patient receiving cancer immunotherapy.

Global Microbiome Drugs Market Scope: Inquire before buying

Global Microbiome Drugs Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2029
Historical Data: 2017 to 2021 Market Size in 2021: US $ 266.07 Mn.
Forecast Period 2022 to 2029 CAGR: 15% Market Size in 2029: US $ 813.93 Mn.
Segments Covered: by Product Type • Probiotics • Prebiotics • Symbiotics • Other Products
by Application • Therapeutics • Diagnostic
by Disease • Autoimmune diseases • Inflammatory bowel diseases • Cancer • Others

Global Microbiome Drugs Market, by Region

• North America • Europe • South America • MEA • APAC

Global Microbiome Drugs Market Key Players

Seres Therapeutics • MaaT Pharma • Enterome Bioscience • MicroBiome Therapeutics LLC • Ritter Pharmaceuticals • Rebiotix, Inc. • Second Genome • OpenBiome • 4D Pharma • Ferring Pharmaceuticals • ViThera Pharmaceuticals • Vedanta BioSciences • Synlogic (US) • Yakult Honsha Co., Ltd. • Osel Inc. • Eligo Bioscience • Merck & Co., Inc. Frequently Asked Questions: 1. Which region has the largest share in Global Microbiome Drugs Market? Ans: North American region holds the highest share in 2021. 2. What is the growth rate of Global Microbiome Drugs Market? Ans: The Global Microbiome Drugs Market is growing at a CAGR of 15% during forecasting period 2022-2029. 3. What is scope of the Global Microbiome Drugs market report? Ans: Global Microbiome Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Microbiome Drugs market? Ans: The important key players in the Global Microbiome Drugs Market are – Seres Therapeutics, MaaT Pharma, Enterome Bioscience, MicroBiome Therapeutics LLC, Ritter Pharmaceuticals, Rebiotix, Inc., Second Genome, OpenBiome, 4D Pharma, Ferring Pharmaceuticals, ViThera Pharmaceuticals, Vedanta BioSciences, Synlogic (US), Yakult Honsha Co., Ltd., Osel Inc., Eligo Bioscience, Merck & Co., and Inc. 5. What is the study period of this market? Ans: The Global Microbiome Drugs Market is studied from 2021 to 2029.
1.Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Microbiome Drugs Market Size, by Market Value (US$ Mn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2021 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Microbiome Drugs Market 3.4. Geographical Snapshot of the Microbiome Drugs Market, By Manufacturer share 4. Global Microbiome Drugs Market Overview, 2021-2029 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porters Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Products 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Global Microbiome Drugs Market 5. Supply Side and Demand Side Indicators 6. Global Microbiome Drugs Market Analysis and Forecast, 2021-2029 6.1. Global Microbiome Drugs Market Size & Y-o-Y Growth Analysis. 7. Global Microbiome Drugs Market Analysis and Forecasts, 2021-2029 7.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 7.1.1. Probiotics 7.1.2. Prebiotics 7.1.3. Symbiotics 7.1.4. Other Products 7.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 7.2.1. Therapeutics 7.2.2. Diagnostic 7.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 7.3.1. Autoimmune diseases 7.3.2. Inflammatory bowel diseases 7.3.3. Cancer 7.3.4. Others 8. Global Microbiome Drugs Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2021-2029 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Microbiome Drugs Market Analysis and Forecasts, 2021-2029 9.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 9.1.1. Probiotics 9.1.2. Prebiotics 9.1.3. Symbiotics 9.1.4. Other Products 9.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 9.2.1. Therapeutics 9.2.2. Diagnostic 9.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 9.3.1. Autoimmune diseases 9.3.2. Inflammatory bowel diseases 9.3.3. Cancer 9.3.4. Others 10. North America Microbiome Drugs Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2021-2029 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Microbiome Drugs Market Analysis and Forecasts, 2021-2029 11.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 11.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 11.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 12. Canada Microbiome Drugs Market Analysis and Forecasts, 2021-2029 12.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 12.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 12.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 13. Mexico Microbiome Drugs Market Analysis and Forecasts, 2021-2029 13.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 13.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 13.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 14. Europe Microbiome Drugs Market Analysis and Forecasts, 2021-2029 14.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 14.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 14.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 15. Europe Microbiome Drugs Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2021-2029 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K. Microbiome Drugs Market Analysis and Forecasts, 2021-2029 16.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 16.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 16.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 17. France Microbiome Drugs Market Analysis and Forecasts, 2021-2029 17.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 17.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 17.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 18. Germany Microbiome Drugs Market Analysis and Forecasts, 2021-2029 18.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 18.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 18.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 19. Italy Microbiome Drugs Market Analysis and Forecasts, 2021-2029 19.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 19.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 19.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 20. Spain Microbiome Drugs Market Analysis and Forecasts, 2021-2029 20.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 20.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 20.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 21. Sweden Microbiome Drugs Market Analysis and Forecasts, 2021-2029 21.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 21.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 21.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 22. CIS Countries Microbiome Drugs Market Analysis and Forecasts, 2021-2029 22.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 22.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 22.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 23. Rest of Europe Microbiome Drugs Market Analysis and Forecasts, 2021-2029 23.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 23.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 23.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 24. Asia Pacific Microbiome Drugs Market Analysis and Forecasts, 2021-2029 24.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 24.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 24.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 25. Asia Pacific Microbiome Drugs Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2021-2029 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Microbiome Drugs Market Analysis and Forecasts, 2021-2029 26.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 26.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 26.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 27. India Microbiome Drugs Market Analysis and Forecasts, 2021-2029 27.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 27.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 27.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 28. Japan Microbiome Drugs Market Analysis and Forecasts, 2021-2029 28.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 28.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 28.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 29. South Korea Microbiome Drugs Market Analysis and Forecasts, 2021-2029 29.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 29.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 29.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 30. Australia Microbiome Drugs Market Analysis and Forecasts, 2021-2029 30.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 30.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 30.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 31. ASEAN Microbiome Drugs Market Analysis and Forecasts, 2021-2029 31.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 31.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 31.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 32. Rest of Asia Pacific Microbiome Drugs Market Analysis and Forecasts, 2021-2029 32.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 32.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 32.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 33. Middle East Africa Microbiome Drugs Market Analysis and Forecasts, 2021-2029 33.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 33.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 33.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 34. Middle East Africa Microbiome Drugs Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2021-2029 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Microbiome Drugs Market Analysis and Forecasts, 2021-2029 35.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 35.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 35.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 36. GCC Countries Microbiome Drugs Market Analysis and Forecasts, 2021-2029 36.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 36.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 36.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 37. Egypt Microbiome Drugs Market Analysis and Forecasts, 2021-2029 37.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 37.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 37.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 38. Nigeria Microbiome Drugs Market Analysis and Forecasts, 2021-2029 38.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 38.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 38.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 39. Rest of ME&A Microbiome Drugs Market Analysis and Forecasts, 2021-2029 39.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 39.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 39.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 40. South America Microbiome Drugs Market Analysis and Forecasts, 2021-2029 40.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 40.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 40.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 41. South America Microbiome Drugs Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2021-2029 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Microbiome Drugs Market Analysis and Forecasts, 2021-2029 42.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 42.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 42.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 43. Argentina Microbiome Drugs Market Analysis and Forecasts, 2021-2029 43.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 43.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 43.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 44. Rest of South America Microbiome Drugs Market Analysis and Forecasts, 2021-2029 44.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2029 44.2. Market Size (Value) Estimates & Forecast By Application, 2021-2029 44.3. Market Size (Value) Estimates & Forecast By Disease, 2021-2029 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Global Microbiome Drugs Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Applications and R&D Investment 45.2.2. New Product Launches and Product Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements 45.3. Company Profile : Key Players 45.3.1. Seres Therapeutics 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Product Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Developments 45.3.2. MaaT Pharma 45.3.3. Enterome Bioscience 45.3.4. MicroBiome Therapeutics LLC 45.3.5. Ritter Pharmaceuticals 45.3.6. Rebiotix, Inc. 45.3.7. Second Genome 45.3.8. OpenBiome 45.3.9. 4D Pharma 45.3.10. Ferring Pharmaceuticals 45.3.11. ViThera Pharmaceuticals 45.3.12. Vedanta BioSciences 45.3.13. Synlogic (US) 45.3.14. Yakult Honsha Co., Ltd. 45.3.15. Osel Inc. 45.3.16. Eligo Bioscience 45.3.17. Merck & Co., Inc. 46. Primary Key Insights

About This Report

Report ID 100909
Category Healthcare
Published Date Oct 2022
Updated Date
Contact Us